表紙
市場調査レポート

世界の婦人科治療薬市場の分析と予測:ホルモン補充療法に関する望ましくないリスク/便益プロファイルによる、安全で効果的な治療用へのアンメットニーズ

Women's Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy

発行 GBI Research 商品コード 227577
出版日 ページ情報 英文 137 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
世界の婦人科治療薬市場の分析と予測:ホルモン補充療法に関する望ましくないリスク/便益プロファイルによる、安全で効果的な治療用へのアンメットニーズ Women's Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy
出版日: 2012年11月09日 ページ情報: 英文 137 Pages
概要

2011年、世界の婦人科疾患治療薬市場は188億米ドルになると推計されています。更に、同市場は2017年まで年平均(CAGR)2.7%の速度で拡大し、2017年には227億米ドルに達する見込みです。

当レポートでは、全世界の婦人科疾患市場について分析し、全体的な市場構造・動向や、地域別・疾患別の詳細動向(市場収益、ジェネリック医薬品のシェア、年間治療費、治療法の利用形態、市販薬剤、市場促進・阻害因子)、製品のパイプライン評価、競争環境、主な資本取引・事業提携の動向などをまとめ、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • イントロダクション
  • 収益予測
    • 収益
    • 年間治療費
    • ブランド薬/ジェネリック医薬品のシェア
  • 治療の利用パターン
  • 市場促進因子・阻害因子

第4章 地域別情勢

  • 米国(収益、年間治療費、治療法の利用形態)
  • 欧州5ヶ国
  • 日本
  • オーストラリア
  • インド
  • 中国

第5章 治療情勢

  • 更年期障害
  • 閉経後骨粗鬆症
  • 子宮内膜症
  • 不妊症
  • 女性用避妊薬

第6章 パイプライン分析

  • イントロダクション
  • 研究開発パイプライン:更年期障害
  • 研究開発パイプライン:閉経後骨粗鬆症
  • 研究開発パイプライン:子宮内膜症
  • 研究開発パイプライン:不妊症
  • 研究開発パイプライン:女性の性的機能不能
  • 研究開発パイプライン:避妊
  • 将来有望な薬剤のプロファイル
    • Menerba
    • Odanacatib
    • Elagolix
    • Libigel
    • Femprox
    • MK 8962
    • Zoely
    • AMG 785

第7章 競合情勢

  • 市場シェア分析:婦人科疾患市場
  • 競合プロファイル
    • Warner Chilcott
    • Pfizer
    • Eli-Lilly
    • Merck
    • Roche
    • Bayer

第8章 戦略的な企業統合

  • 概要
  • 年度別件数
  • 種類別件数
  • 金額別件数
  • 企業合併・買収(M&A)
  • ライセンス契約
  • パートナーシップ

第9章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC248MR

Summary

GBI Research, a leading business intelligence provider, has released its latest research, "Women's Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy", which provides insights into the women's health therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts. It provides an in-depth analysis of the major diseases, and includes coverage of menopause, postmenopausal osteoporosis, endometriosis, infertility, and female contraceptives. The report provides in-depth analysis of the drivers and barriers that affect the global women's health market, and analyzes the markets for women's health disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. The report also analyzes the women's health therapeutics market in India, China and Australia. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global market.

In 2011, the women's health therapeutics market was estimated to be worth $18.8 billion. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 2.7% between 2011 and 2018, to record a sales value of $22.7 billion in 2018. The patent expiries of blockbusters such as Evista, the Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and others during the forecast period are expected to slow down the market growth for the women's health therapeutics market. The launch of novel molecules like Elagolix and Odanacatib in the late stage pipeline will drive the market in the forecast period.

The women's health therapeutics market R&D pipeline shows promising molecules. The current treatment options for women's disorders are limited due to lack of safety. The unmet need in the women's disorders market is attracting the pharmaceutical companies to invest in R&D programs. Increased focus is seen on therapy areas such as menopause, female sexual dysfunction and infertility.

Scope

  • Annualized market data for the women's health disorders market from 2003 to 2011, with forecasts to 2018.
  • Analysis of the leading therapeutic segments, including menopause, postmenopausal osteoporosis, endometriosis, infertility, and the female contraceptives market.
  • Analysis of the women's health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the women's health therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of drug development.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck, Bayer and Warner Chilcott Plc.
  • Key M&A activities and licensing agreements that took place in the years 2010 to 2012 in the women's health therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Executive Summary

Demand Grows for Alternative to Hormone Therapy in Menopausal Women.

There is room for improvement in the female health disorders market, and this is fuelling pharmaceutical companies to invest in R&D programs, stated a new report by healthcare experts GBI Research.

The new report* states that increased focus is being shown in therapy areas such as menopause, female sexual dysfunction and infertility, as large target markets and unsatisfactory existing treatments make patients a willing target for new treatments.

The ageing population is driving the menopause therapeutics market, as menopausal symptoms often emerge after the age of 50, with indications such as hot flashes affecting up to 85% of menopausal women. As the population grows older, the number of postmenopausal women will increase.

The menopause therapeutics market is currently dominated by hormone therapies with highly questionable safety profiles. Patients as well as physicians are often reluctant to try hormone therapy as the first line treatment for menopausal symptoms and osteoporosis, as a result of studies such as the WHI Memory Study (WHIMS), the Estrogen Replacement and Atherosclerosis (ERA) study, and the Million Women Study, which have all raised concerns over the safety profile of hormone treatment (HT). Results suggested that hormone treatment (HT) was associated with an increased risk of breast cancer, venous thromboembolism and stroke. The availability of alternative options such as lifestyle and diet changes, exercise and home remedies has also damaged the hormone therapy market, as despite the severity of postmenopausal symptoms, a majority of postmenopausal women tend to opt for home remedies and lifestyle changes rather than using hormone therapy.

Aprela is a progesterone-free treatment for menopausal symptoms which combines conjugated estrogens and bazedoxifene. The drug is currently under review by the US FDA for approval, and is predicted to restore the HT market with peak sales of approximately $1 billion after its expected approval next year. Aprela has shown favorable results in initial studies in comparison to other HT therapeutics, with studies suggesting that Aprela may pose fewer risks and milder side effects than Prempro and Premarin, and no evidence of breast tenderness and pain or increased breast cancer rates as compared to Evista. Other studies revealed that Aprela recipients experienced better sleep and diminished hot flashes compared to women who were treated with a placebo. The drug may therefore provide a better line of treatment for postmenopausal women. Once approved, the treatment is expected to compete strongly with medication currently on offer, significantly altering the menopause market dynamics.

Progression is also being made in the treatment of related menopausal conditions. The female sexual dysfunction therapeutics market currently does not have any FDA approved drugs that are comparable to Viagra for males, but there are many promising molecules in the late stage development phase, most of which have demonstrated high safety and efficacy profiles in clinical trials. If these new therapies can cater to the significant unmet need associated with current treatment options for female sexual dysfunction, they can command a price premium and drive the women's therapy market.

Steps are also being made in the postmenopausal osteoporosis market, with Amgen Inc recently launching first-in-class drug Prolia, and Merck's cathepsin K inhibitor Odanacatib (MK-0822) also showing promising results.

The women's health therapeutics market, including treatments for postmenopausal osteoporosis, hormone replacement therapy, infertility, contraceptives and endometriosis, was valued at $18.8 billion in 2011.

This report provides insights into the women's health therapeutics market until 2018.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Women's Health Therapeutics Market to 2018 - Introduction

  • 2.1. Overview

3. Women's Health Therapeutics Market to 2018 - Market Overview

  • 3.1. Introduction
  • 3.2. Revenue Forecasts for the Women's Health Therapeutics Market
    • 3.2.1. Revenues
    • 3.2.2. Annual Cost of Therapy
    • 3.2.3. Branded and Generic Market Share
  • 3.3. Treatment Usage Patterns
  • 3.4. Drivers and Barriers for the Women's Health Therapeutics Market
    • 3.4.1. Drivers for the Women's Health Therapeutics Market
    • 3.4.2. Barriers for the Women's Health Therapeutics Market

4. Women's Health Therapeutics Market to 2018 - Geographical Landscape

  • 4.1. The US
    • 4.1.1. Revenue
    • 4.1.2. Annual Cost of Therapy
    • 4.1.3. Treatment Usage Pattern
  • 4.2. Top Five Countries of Europe
    • 4.2.1. Revenue
    • 4.2.2. Annual Cost of Therapy
    • 4.2.3. Treatment Usage Pattern
  • 4.3. Japan
    • 4.3.1. Revenue
    • 4.3.2. Annual Cost of Therapy
    • 4.3.3. Treatment Usage Pattern
  • 4.4. Women's Health Therapeutics Market, Australia - Overview
    • 4.4.1. Epidemiology
    • 4.4.2. Clinical Trials
    • 4.4.3. Drivers and Restraints
  • 4.5. Women's Health Therapeutics Market, India - Overview
    • 4.5.1. Epidemiology
    • 4.5.2. Clinical Trials
    • 4.5.3. Drivers and Restraints
  • 4.6. Women's Health Therapeutics Market, China - Overview
    • 4.6.1. Epidemiology
    • 4.6.2. Clinical Trials
    • 4.6.3. Drivers and Restraints

5. Women's Health Therapeutics Market to 2018 - Therapeutic Landscape

  • 5.1. Menopause
    • 5.1.1. Introduction
    • 5.1.2. Revenues
    • 5.1.3. Branded and Generic Market Share
    • 5.1.4. Annual Cost of Therapy
    • 5.1.5. Treatment Usage Patterns
    • 5.1.6. Major Marketed Products in the Menopause Therapeutics Market
    • 5.1.7. Drivers for the Menopause Therapeutics Market
    • 5.1.8. Barriers for the Menopause Therapeutics Market
  • 5.2. Postmenopausal Osteoporosis
    • 5.2.1. Introduction
    • 5.2.2. Revenues
    • 5.2.3. Branded versus Generic Market Share
    • 5.2.4. Annual Cost of Therapy
    • 5.2.5. Treatment Usage Patterns
    • 5.2.6. Treatment Flow Algorithm
    • 5.2.7. Major Marketed Drugs in the Postmenopausal Osteoporosis Market
    • 5.2.8. Drivers for the Postmenopausal Osteoporosis Market
    • 5.2.9. Barriers for the Postmenopausal Osteoporosis Market
  • 5.3. Endometriosis
    • 5.3.1. Introduction
    • 5.3.2. Revenues
    • 5.3.3. Branded and Generic Market Share
    • 5.3.4. Annual Cost of Therapy
    • 5.3.5. Treatment Usage Patterns
    • 5.3.6. Treatment Flow Algorithm
    • 5.3.7. Major Marketed Drugs for Endometriosis
    • 5.3.8. Drivers for the Endometriosis Therapeutics Market
    • 5.3.9. Barriers for the Endometriosis Therapeutics Market
  • 5.4. Infertility
    • 5.4.1. Introduction
    • 5.4.2. Revenues
    • 5.4.3. Branded and Generic Market Share
    • 5.4.4. Annual Cost of Therapy
    • 5.4.5. Treatment Usage Patterns
    • 5.4.6. Treatment Flow Algorithm
    • 5.4.7. Major Marketed Drugs in the Infertility Therapeutics Market
    • 5.4.8. Drivers for the Infertility Therapeutics Market
    • 5.4.9. Barriers for the Infertility Therapeutics Market
  • 5.5. Female Contraceptives
    • 5.5.1. Introduction
    • 5.5.2. Revenues
    • 5.5.3. Share of Prescription and OTC Contraceptives
    • 5.5.4. Annual Cost of Usage
    • 5.5.5. Treatment Usage Patterns
    • 5.5.6. Major Marketed Products in the Female Contraceptives Market
    • 5.5.7. Drivers for the Female Contraceptives Market
    • 5.5.8. Barriers for the Female Contraceptives Market

6. Women's Health Therapeutics Market to 2018 - Pipeline Analysis

  • 6.1. Overview
  • 6.2. Research and Development Pipeline - Menopause
    • 6.2.1. Overview
  • 6.3. Research and Development Pipeline - Postmenopausal Osteoporosis
    • 6.3.1. Overview
  • 6.4. Research and Development Pipeline - Endometriosis
    • 6.4.1. Overview
  • 6.5. Research and Development Pipeline - Infertility
    • 6.5.1. Overview
  • 6.6. Research and Development Pipeline - Female Sexual Dysfunction
    • 6.6.1. Overview
  • 6.7. Research and Development Pipeline - Contraceptives
    • 6.7.1. Overview
  • 6.8. Profiles of Promising Drugs in the Women's Health Therapeutics Market
    • 6.8.1. Menerba
    • 6.8.2. Odanacatib
    • 6.8.3. Elagolix
    • 6.8.4. Libigel
    • 6.8.5. Femprox
    • 6.8.6. MK 8962
    • 6.8.7. Zoely
    • 6.8.8. AMG 785

7. Women's Health Therapeutics Market to 2018 - Competitive Landscape

  • 7.1. Market Share Analysis: Women's Health Therapeutics Market
  • 7.2. Competitive Profiling
    • 7.2.1. Warner Chilcott
    • 7.2.2. Pfizer
    • 7.2.3. Eli-Lilly
    • 7.2.4. Merck
    • 7.2.5. Roche
    • 7.2.6. Bayer

8. Women's Health Therapeutics Market to 2018 - Strategic Consolidations

  • 8.1. Overview
  • 8.2. Deals by Year
  • 8.3. Deals by Type
  • 8.4. Deals by Value
  • 8.5. Mergers and Acquisitions
    • 8.5.1. Major M&A Deals
  • 8.6. Licensing Agreements
    • 8.6.1. Major Licensing Agreements
  • 8.7. Partnerships
    • 8.7.1. Major Partnership Deals

9. Women's Health Therapeutics Market to 2018 - Appendix

  • 9.1. Abbreviations
  • 9.2. Market Definitions
  • 9.3. Bibliography
  • 9.4. Research Methodology
    • 9.4.1. Coverage
    • 9.4.2. Secondary Research
    • 9.4.3. Primary Research
    • 9.4.4. Expert Panel Validation
    • 9.4.5. Section-wise Research Methodology
  • 9.5. Therapeutic Landscape
    • 9.5.2. Market Size by Geography
  • 9.6. Geographical Landscape
  • 9.7. Pipeline Analysis
  • 9.8. Competitive Landscape
  • 9.9. Strategic Consolidations
  • 9.10. Contact Us
  • 9.11. Disclaimer

List of Tables

  • Table 1: Women's Health Therapeutics Market, Global, Revenue ($bn), 2003-2011
  • Table 2: Women's Health Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
  • Table 3: Women's Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
  • Table 4: Women's Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 5: Women's Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
  • Table 6: Women's Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
  • Table 7: Women's Health Therapeutics Market, The US, Revenue ($bn), 2003-2011
  • Table 8: Women's Health Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018
  • Table 9: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2011
  • Table 10: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2018
  • Table 11: Women's Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2003-2011
  • Table 12: Women's Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2018
  • Table 13: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2003-2011
  • Table 14: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018
  • Table 15: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2011
  • Table 16: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011-2018
  • Table 17: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2003-2011
  • Table 18: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2011-2018
  • Table 19: Women's Health Therapeutics Market, Japan, Revenue ($m), 2003-2011
  • Table 20: Women's Health Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018
  • Table 21: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2011
  • Table 22: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018
  • Table 23: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2003-2011
  • Table 24: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2018
  • Table 25: Women's Health Therapeutics Market, Pipeline Molecules, Australia, 2012
  • Table 26: Women's Health Therapeutics Market, Pipeline Molecules, India, 2012
  • Table 27: Women's Health Therapeutics Market, Pipeline Molecules, China, 2012
  • Table 28: Menopause Therapeutics Market, Global, Revenue ($m), 2003-2011
  • Table 29: Menopause Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 30: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011
  • Table 31: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2011-2018
  • Table 32: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
  • Table 33: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 34: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
  • Table 35: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
  • Table 36: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2003-2011
  • Table 37: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
  • Table 38: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2003-2011
  • Table 39: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2011-2018
  • Table 40: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
  • Table 41: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 42: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
  • Table 43: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
  • Table 44: Postmenopausal Osteoporosis Therapeutics Market, Major Marketed Drug Revenues, 2011
  • Table 45: Endometriosis Therapeutics Market, Global, Revenue ($m), 2003-2011
  • Table 46: Endometriosis Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 47: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011
  • Table 48: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2011-2018
  • Table 49: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
  • Table 50: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 51: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
  • Table 52: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
  • Table 53: Infertility Therapeutics Market, Global, Revenue ($m), 2003-2011
  • Table 54: Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 55: Infertility Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011
  • Table 56: Infertility Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2011-2018
  • Table 57: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
  • Table 58: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 59: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
  • Table 60: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
  • Table 61: Infertility Therapeutics Market, Major Marketed Drug Revenues ($m), 2011
  • Table 62: Efficacy Outcome by Treatment Groups in Ovulation Induction for Study FPI FSH 99-03 (One Cycle of Treatment)
  • Table 63: Efficacy Outcome for IVF Study FPI FSH 2001-01 (One Cycle of Treatment)
  • Table 64: Contraceptives Market, Global, Revenue ($bn), 2003-2011
  • Table 65: Contraceptives Market, Global, Revenue Forecasts ($bn), 2011-2018
  • Table 66: Contraceptives Market, Global, Revenue by Type ($m), 2003-2011
  • Table 67: Contraceptives Market, Global, Revenue Forecasts by Type ($m), 2011-2018
  • Table 68: Contraceptives Market, Global, Revenue by Geographical Segmentation ($m), 2003-2011
  • Table 69: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018
  • Table 70: Contraceptives Market, Global, Annual Cost of Usage ($), 2003-2011
  • Table 71: Contraceptives Market, Global, Annual Cost of Usage ($), 2011-2018
  • Table 72: Contraceptives Market, Global, Treatment Usage Patterns (million), 2003-2011
  • Table 73: Contraceptives Market, Global, Treatment Usage Patterns (million), 2011-2018
  • Table 74: Contraceptives Market, Major Marketed Drug Market Share, 2011
  • Table 75: Women's Health Therapeutics Market, Global, Pipeline by Phase (%), 2012
  • Table 76: Women's Health Therapeutics Market, Global, Pipeline by Indication (%), 2012
  • Table 77: Women's Health Therapeutics Market, Global, Pipeline Analysis, Most Promising Molecules, 2012
  • Table 78: Women's Health Therapeutics Market, Warner Chilcott, Major Marketed Products, 2011
  • Table 79: Women's Health Therapeutics Market, Pfizer, Major Marketed Products, 2011
  • Table 80: Women's Health Therapeutics Market, Eli Lilly, Major Marketed Products, 2011
  • Table 81: Women's Health Therapeutics Market, Merck, Major Marketed Products, 2011
  • Table 82: Women's Health Therapeutics Market, Roche, Major Marketed Products, 2011
  • Table 83: Women's Health Therapeutics Market, Bayer, Major Marketed Products, 2011
  • Table 84: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Mergers and Acquisitions, 2010-2012
  • Table 85: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Agreements, 2010-2012
  • Table 86: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Partnerships, 2010-2012

List of Figures

  • Figure 1: Women's Health Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2018
  • Figure 2: Women's Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
  • Figure 3: Women's Health Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
  • Figure 4: Women's Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
  • Figure 5: Women's Health Therapeutics Market, Global, Drivers and Barriers
  • Figure 6: Women's Health Therapeutics Market, The US, Revenue Forecasts ($bn), 2003-2018
  • Figure 7: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2018
  • Figure 8: Women's Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2003-2018
  • Figure 9: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2003-2018
  • Figure 10: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2018
  • Figure 11: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2003-2018
  • Figure 12: Women's Health Therapeutics Market, Japan, Revenue Forecasts ($m), 2003-2018
  • Figure 13: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2018
  • Figure 14: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2003-2018
  • Figure 15: Menopause Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018
  • Figure 16: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018
  • Figure 17: Menopause Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
  • Figure 18: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
  • Figure 19: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
  • Figure 20: Menopause Therapeutics Market, Global, Drivers and Barriers
  • Figure 21: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2018
  • Figure 22: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2003-2018
  • Figure 23: Postmenopausal Osteoporosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
  • Figure 24: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
  • Figure 25: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
  • Figure 26: Postmenopausal Osteoporosis Therapeutics Market, Treatment Flow Algorithm
  • Figure 27: Postmenopausal Osteoporosis Therapeutics Market, Major Marketed Drug Market Share, 2011
  • Figure 28: Postmenopausal Osteoporosis Therapeutics Market, Global, Drivers and Barriers
  • Figure 29: Endometriosis Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018
  • Figure 30: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018
  • Figure 31: Endometriosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
  • Figure 32: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
  • Figure 33: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
  • Figure 34: Endometriosis Therapeutics Market, Treatment Flow Algorithm
  • Figure 35: Endometriosis Therapeutics Market, Global, Drivers and Barriers
  • Figure 36: Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018
  • Figure 37: Infertility Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018
  • Figure 38: Infertility Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
  • Figure 39: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
  • Figure 40: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
  • Figure 41: Infertility Therapeutics Market, Treatment Flow Algorithm
  • Figure 42: Infertility Therapeutics Market, Global, Drivers and Barriers
  • Figure 43: Contraceptives Market, Global, Revenue Forecasts ($bn), 2003-2018
  • Figure 44: Contraceptives Market, Global, Revenue Forecasts by Type ($m), 2003-2018
  • Figure 45: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2003-2018
  • Figure 46: Contraceptives Market, Global, Share of Prescription and OTC Contraceptives (%), 2011
  • Figure 47: Contraceptives Market, Global, Annual Cost of Usage ($), 2003-2018
  • Figure 48: Contraceptives Market, Global, Treatment Usage Patterns (million), 2003-2018
  • Figure 49: Contraceptives Market, Major Marketed Drug Market Share, 2011
  • Figure 50: Contraceptives Market, Global, Drivers and Barriers
  • Figure 51: Women's Health Therapeutics Market, Global, Pipeline by Phase (%), 2012
  • Figure 52: Women's Health Therapeutics Market, Global, Pipeline by Indication (%), 2012
  • Figure 53: Menopause Therapeutics Market, Global, Pipeline by Phase (%), 2012
  • Figure 54: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline by Phase (%), 2012
  • Figure 55: Endometriosis Therapeutics Market, Global, Pipeline by Indication (%), 2012
  • Figure 56: Infertility Therapeutics Market, Global, Pipeline by Indication (%), 2012
  • Figure 57: Female Sexual Dysfunction Therapeutics Market, Global, Pipeline by Indication (%), 2012
  • Figure 58: Female Contraceptives Market, Global, Pipeline by Indication (%), 2012
  • Figure 59: Women's Health Therapeutics Market, Global, Market Share of Companies (%), 2011
  • Figure 60: Women's Health Therapeutics Market, Warner Chilcott SWOT Analysis, 2012
  • Figure 61: Women's Health Therapeutics Market, Pfizer SWOT Analysis, 2012
  • Figure 62: Women's Health Therapeutics Market, Eli Lilly SWOT Analysis, 2012
  • Figure 63: Women's Health Therapeutics Market, Merck SWOT Analysis, 2012
  • Figure 64: Women's Health Therapeutics Market, Roche SWOT Analysis, 2012
  • Figure 65: Women's Health Therapeutics Market, Bayer SWOT Analysis, 2012
  • Figure 66: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Year, 2010-2012
  • Figure 67: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type, 2010-2012
  • Figure 68: Women's Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value, 2010-2012
  • Figure 69: GBI Research Market Forecasting Model
Back to Top